Peter Schmid1,2, Jacinta Abraham3, Stephen Chan4, Duncan Wheatley5, Adrian Murray Brunt6, Gia Nemsadze7, Richard D Baird8, Yeon Hee Park9, Peter S Hall10, Timothy Perren11, Robert C Stein12, László Mangel13, Jean-Marc Ferrero14, Melissa Phillips2, John Conibear2, Javier Cortes15, Andrew Foxley16, Elza C de Bruin16, Robert McEwen16, Daniel Stetson17, Brian Dougherty17, Shah-Jalal Sarker1, Aaron Prendergast1, Max McLaughlin-Callan1, Matthew Burgess1, Cheryl Lawrence1, Hayley Cartwright1, Kelly Mousa1, Nicholas C Turner18,19. 1. Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. 2. Barts Hospital NHS Trust, London, United Kingdom. 3. Velindre National Health Service (NHS) Trust, Cardiff, United Kingdom. 4. Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. 5. Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom. 6. University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom. 7. Institute of Clinical Oncology, Tbilisi, Georgia. 8. Cancer Research UK Cambridge Centre, Cambridge, United Kingdom. 9. Samsung Medical Centre, Seoul, Republic of Korea. 10. Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom. 11. Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. 12. National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, University College London, London, United Kingdom. 13. Institute of Oncology, Medical University of Pécs, Pecs, Hungary. 14. Centre Antoine Lacassagne, Nice, France. 15. Ramon y Cajal University Hospital, Madrid, Spain. 16. AstraZeneca, Cambridge, United Kingdom. 17. AstraZeneca, Waltham, MA. 18. Institute of Cancer Research, London, United Kingdom. 19. Royal Marsden Hospital, London, United Kingdom.
Abstract
PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC. PATIENTS AND METHODS: This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/AKT1/PTEN alterations, tumor response, and safety. RESULTS:Median PFS was 5.9 months with capivasertib plus paclitaxel and 4.2 months with placebo plus paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided P = .10]). Median OS was 19.1 months with capivasertib plus paclitaxel and 12.6 months with placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99; 2-sided P = .04). In patients with PIK3CA/AKT1/PTEN-altered tumors (n = 28), median PFS was 9.3 months with capivasertib plus paclitaxel and 3.7 months with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01). The most common grade ≥ 3 adverse events in those treated with capivasertib plus paclitaxel versus placebo plus paclitaxel, respectively, were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%). CONCLUSION: Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more pronounced in patients with PIK3CA/AKT1/PTEN-altered tumors. Capivasertib warrants further investigation for treatment of TNBC.
RCT Entities:
PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC. PATIENTS AND METHODS: This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/AKT1/PTEN alterations, tumor response, and safety. RESULTS: Median PFS was 5.9 months with capivasertib plus paclitaxel and 4.2 months with placebo plus paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided P = .10]). Median OS was 19.1 months with capivasertib plus paclitaxel and 12.6 months with placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99; 2-sided P = .04). In patients with PIK3CA/AKT1/PTEN-altered tumors (n = 28), median PFS was 9.3 months with capivasertib plus paclitaxel and 3.7 months with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01). The most common grade ≥ 3 adverse events in those treated with capivasertib plus paclitaxel versus placebo plus paclitaxel, respectively, were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%). CONCLUSION: Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more pronounced in patients with PIK3CA/AKT1/PTEN-altered tumors. Capivasertib warrants further investigation for treatment of TNBC.
Authors: Albert Gris-Oliver; Marta Palafox; Mafalda Oliveira; Violeta Serra; Laia Monserrat; Fara Brasó-Maristany; Andreu Òdena; Mònica Sánchez-Guixé; Yasir H Ibrahim; Guillermo Villacampa; Judit Grueso; Mireia Parés; Marta Guzmán; Olga Rodríguez; Alejandra Bruna; Caroline S Hirst; Alan Barnicle; Elza C de Bruin; Avinash Reddy; Gaia Schiavon; Joaquín Arribas; Gordon B Mills; Carlos Caldas; Rodrigo Dienstmann; Aleix Prat; Paolo Nuciforo; Pedram Razavi; Maurizio Scaltriti; Nicholas C Turner; Cristina Saura; Barry R Davies Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531
Authors: Rebecca Dent; Mafalda Oliveira; Steven J Isakoff; Seock-Ah Im; Marc Espié; Sibel Blau; Antoinette R Tan; Cristina Saura; Matthew J Wongchenko; Na Xu; Denise Bradley; Sarah-Jayne Reilly; Aruna Mani; Sung-Bae Kim Journal: Breast Cancer Res Treat Date: 2021-07-15 Impact factor: 4.872
Authors: Argun Akcakanat; Xiaofeng Zheng; Christian X Cruz Pico; Tae-Beom Kim; Ken Chen; Anil Korkut; Aysegul Sahin; Vijaykumar Holla; Emily Tarco; Gopal Singh; Senthil Damodaran; Gordon B Mills; Ana Maria Gonzalez-Angulo; Funda Meric-Bernstam Journal: Clin Cancer Res Date: 2021-03-29 Impact factor: 12.531
Authors: Priyanka Sharma; Vandana G Abramson; Anne O'Dea; Lauren Nye; Ingrid Mayer; Harsh B Pathak; Marc Hoffmann; Shane R Stecklein; Manana Elia; Sharon Lewis; Jecinta Scott; Jilliann A De Jong; Yen Y Wang; Rachel Yoder; Kelsey Schwensen; Karissa Finke; Jaimie Heldstab; Stephanie LaFaver; Stephen K Williamson; Milind A Phadnis; Gregory A Reed; Bruce F Kimler; Qamar J Khan; Andrew K Godwin Journal: Clin Cancer Res Date: 2021-02-18 Impact factor: 12.531
Authors: Mercedes Herrera Juarez; Pablo Tolosa Ortega; Ana Sanchez de Torre; Eva Ciruelos Gil Journal: Breast Care (Basel) Date: 2020-06-05 Impact factor: 2.860